Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 11;4(3):813-826.
doi: 10.3390/nano4030813.

Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities

Xin Xia  1   2 , Kevin Pethe  3 , Ryangyeo Kim  4 , Lluis Ballell  5 , David Barros  6 , Jonathan Cechetto  7 , HeeKyoung Jeon  8 , Kideok Kim  9 , Alfonso E Garcia-Bennett  10
Affiliations

Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities

Xin Xia et al. Nanomaterials (Basel). .

Abstract

Tuberculosis is a major problem in public health. While new effective treatments to combat the disease are currently under development, they tend suffer from poor solubility often resulting in low and/or inconsistent oral bioavailability. Mesoporous materials are here investigated in an in vitro intracellular assay, for the effective delivery of compound PA-824; a poorly soluble bactericidal agent being developed against Tuberculosis (TB). Mesoporous materials enhance the solubility of PA-824; however, this is not translated into a higher antibacterial activity in TB-infected macrophages after 5 days of incubation, where similar values are obtained. The lack of improved activity may be due to insufficient release of the drug from the mesopores in the context of the cellular environment. However, these results show promising data for the use of mesoporous particles in the context of oral delivery with expected improvements in bioavailability.

Keywords: formulation; intracellular; mesoporous materials; nanomedicine; solubility; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

AEGB is the co-founder of Nanologica AB (Stockholm, Sweden) a company commercializing nanoporous materials for biomedical and related applications and, therefore, has a potential conflict of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article apart from those disclosed.

Figures

Figure 1
Figure 1
Molecular structure of (a) PA-824 and (b) moxifloxacin; (c) scanning and (d) transmission electron microscopy images of typical particles of calcined AMS-6.
Scheme I
Scheme I
Scheme of the experimental design, silica particles loaded with PA-824 or moxifloxacin are presented to infected macrophages for the evaluation of the antibacterial activity of the free drug and encapsulated drug.
Figure 2
Figure 2
X-ray diffraction patterns of (a) free moxifloxacin, and AMS-6-Moxi; (b) free PA-824, and AMS-6-PA824. Both show that the free drug in its crystalline state and the encapsulated material contains drug in the amorphous state; (c) differential scanning calorimetry (DSC) curves of free and loaded PA-824; (d) pore size distribution of calcined AMS-6, AMS-6-PA824, and AMS-6-Moxi obtained from density functional theory (DFT).
Figure 3
Figure 3
Kinetic release curves of (a) free and encapsulated moxifloxacin and (b) PA-824; in phosphate buffered saline buffer (PBS buffer, 10 mg/L).
Figure 4
Figure 4
Antibacterial activity percentage of (a) PA-824; (b) moxifloxacin; (c) AMS-6-PA824; and (d) AMS-6-Moxi. Total macrophages number after present them to drugs in different concentrations: (e) PA-824; (f) moxifloxacin; (g) AMS-6-PA824; and (h) AMS-6-Moxi (Concentration in logarithm scale).
Figure 5
Figure 5
Confocal microscopy images of intracellular growth of tubercle bacilli inside macrophages under the treatment of PA-824, moxifloxacin, encapsulated PA-824, and encapsulate moxifloxacin at different drug concentration. Green-bacteria with green fluorescence; Red-alive macrophages.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Tuberculosis WHO Global Tuberculosis Report 2013. [(accessed on 22 March 2013)]. Available online: http://www.who.int/tb/publications/factsheet_global.pdf?ua=1.2013.
    1. McGrath M., Gey van Pittius N.C., van Helden P.D., Warren R.M., Warner D.F. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 2014;69:292–302. doi: 10.1093/jac/dkt364. - DOI - PubMed
    1. Stover C.K., Warrener P., VanDevanter D.R., Sherman D.R., Arain T.M., Langhorne M.H., Anderson S.W., Towell J.A., Yuan Y., McMurray D.N., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405:962–966. doi: 10.1038/35016103. - DOI - PubMed
    1. Lenaerts A.J., Gruppo V., Marietta K.S., Johnson C.M., Driscoll D.K., Nicholas M., Rose J.D., Reynolds R.C., Ian M., Tompkins N.M., et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series. Antimicrob. Agents Chemother. 2005;49:2294–2301. doi: 10.1128/AAC.49.6.2294-2301.2005. - DOI - PMC - PubMed
    1. Nuermberger E., Tyagi S., Tasneen R., Williams K.N., Almeida D., Rosenthal I., Grosset J.H. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008;52:1522–1524. doi: 10.1128/AAC.00074-08. - DOI - PMC - PubMed